The real time spectrum is required for analysis of properties of matter in an electromagnetic state, bandwidth, sensitivity and frequency range. System developers and signal analysts require this study to understand various signal qualities and to check for any abnormalities in the signal strength present or not.
Agilent’s RTSA will be particularly useful in applications such as radar, electronic warfare and military communications, since the study of the signal strength is crucial for these applications. Hence, these new real-time spectrum analyses will likely offer the most accurate measurement.
Further, for more in-depth analysis, the RTSA can be used with Agilent’s 89600 VSA software. The combination of the spectrum analyzer with the software will enable system developers and signal analysts to locate the cause of signal problems so that real time signals do not get disrupted, which can be critical in some situations.
Thus, Agilent’s continued drive toward a steady flow of new products may prove to be beneficial as the study of signal quality and spectrum analysis is becoming quite crucial.
Agilent’s revenue in the third quarter was flat sequentially and up 1.9% year over year, short of management’s expectations of a 2-3% sequential increase ($1.77 billion to $1.79 billion). The newly added Diagnostics and Genomics segment accounted for 9.0% of revenues in the last quarter, up 47.2% sequentially.
Currently, Agilent Technologies has a Zacks Rank #3 (Hold). Other test equipment companies, which are currently better positioned include National Instruments Corporation (NATI), with a Zacks Rank #1 (Strong Buy) and Ametek Inc. (AME) and On Semiconductor (ONNN), with a Zacks Rank #2 (Buy).
More From Zacks.com